These findings indicate that co‐administration of ABC294640 and ABT‐199 markedly reduces in vivo myeloma tumor growth associated with the down‐regulation of Mcl‐1, c‐Myc, Bcl‐2, and Bcl‐xL. This evidence concerns the gene BCL2 and plasma cell myeloma.